The bill signifies a substantial shift in how terminal illness treatments are approached within the state, encouraging the use of investigational drugs while providing protections for both patients and physicians. Notably, it does not obligate healthcare insurers or state agencies to cover the costs associated with these investigational therapies, potentially limiting practical access for some patients. However, the bill also provides legal immunity for physicians who recommend these treatments, thereby alleviating concerns surrounding potential liability when accessing unapproved therapies.
Summary
House Bill 1300, known as the Terminal Patients' Right to Try Act, aims to provide terminally ill patients with the legal right to access experimental treatments that have not yet received full approval from the FDA. The bill revises existing criteria and definitions under RSA 126-Z, specifically broadening the eligibility for patients who seek investigational drugs, biologics, or devices. As it stands, patients must demonstrate that they meet specific health conditions and have exhausted approved treatment options before accessing these investigational therapies.
Contention
There are notable points of contention related to the bill, notably around patient safety and the ethical implications of allowing access to unapproved treatments. While proponents argue that this bill offers hope to patients at the end of their treatment options, critics express concerns regarding the adequacy of medical safeguards. Ensuring that terminal patients are adequately informed about the risks and benefits of utilizing investigational therapies remains a critical discussion point. The lack of insurance coverage raises further issues about affordability and access for economically vulnerable patients.
Prohibiting gender transition procedures for minors, relative to sex and gender in public schools, and relative to the definition of conversion therapy.
Expanding the definition of providers who can certify patients of the therapeutic cannabis program and relative to release of a defendant pending trial and relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.